1SHAUNTA D M, KIMI S V, TONI L ,et al. Ripley etoricoxib: a highly selective COX-2 inhibitor[J]. Ann Pharmacother,2005,39 : 854 - 862.
2RIENDEAU M D, PERCIVAL C, BRIDEA U,et al. Etoricoxib etoricoxib ( MK-0663 ) : preelinieal profile and comparison with other agents that selectively inhibit cyclooxygenase-2[ J]. J Pharmacol Exp Ther, 2001, 296: 558.
3JULES I,SCHWART Z, PHAR M D,et al. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 Versus COX-I in healthy subjects [ J ]. J Clin Pharmacol , 2008,48:745-754.
4LAINE L, CURTIS S P, LANGMAN M, et al. Lower gastrointestinal events in a double-blind trial of the cyclooxygenase-2 selective inhibitor etoricoxib and the traditional nonsteroidal anti-inflammatory drug diclofenac [ J ]. Gastroenterology, 2008, 135(5): 1517-1525.
5BINGHAM C O, SEBBA A I, RUBIN B R, et al. Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies [ J ]. Rheumatology, 2007,46 : 496 - 507.
6SCHWARTZ A L, DALLOB P J. Comparative inhibitory activity of etoricoxib, celecoxib, and diclofenac on COX-2 Versus COX-1 in healthy subjects [ J ]. J Clin Pharmacol, 2008,48 : 745 - 754.
7AGRAWAL N G, PORRAS A G, MATrHEWS C Z, et al. Dose proportionality of oral etoricoxib, a highly selective cyclooxygenase-2 inhibitor, in healthy volunteers [ J ]. Clin Pharmacol, 2001,41 : 1106 - 1110.
8DAVID R, RITA A, HALPIN L A,et al. Absorption, metabolism, and excretion of etoricoxib, a potent and selective cyclooxygenase-2 inhibitor, in healthy male volunteers[ J ]. Drug Metab Dispos, 2003, 31 : 224.
9GOTYESDIENER K, SCHNITZER T, FISHER C, et al. Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis [ J ]. Rheumatology, 2002,41 : 1052 - 1061.
10SCHUMACHER H R, JUDITH A B, DAVID I D, et al. Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis [ J ]. BMJ, 2002,324 : 1488 - 1492.
